Radha Rao, MD
Hematology & Oncology · Sioux City, IANPI 1699746016
Payments from drug & device makers
Across 93 payments — averaging $19.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$201
- Seagen Inc.$173
- AbbVie$157
- Genentech USA, Inc.$120
- AstraZeneca$117
- E.r. Squibb & Sons, L.L.C.$105
- plus $933 from 31 others
What the payments were for
- Food & beverage$1,56987%
- Education$23713%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 10 | $201 |
| Seagen Inc. | 6 | $173 |
| AbbVie | 4 | $157 |
| Genentech USA, Inc. | 6 | $120 |
| AstraZeneca | 4 | $117 |
| E.r. Squibb & Sons, L.L.C. | 6 | $105 |
| Pharmaessentia USA Corporation | 5 | $101 |
| Merck | 6 | $97 |
| Amgen | 4 | $54 |
| Daiichi Sankyo Inc. | 2 | $49 |
| Tesaro, Inc. | 2 | $45 |
| Ipsen Biopharmaceuticals, Inc | 1 | $40 |
| Incyte Corporation | 3 | $40 |
| Novartis | 2 | $37 |
| Stemline Therapeutics Inc. | 1 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Servier Pharmaceuticals LLC | 2 | $32 |
| Bristol Myers Squibb | 2 | $32 |
| Sanofi | 2 | $30 |
| Karyopharm Therapeutics Inc. | 2 | $30 |
| GSK | 2 | $28 |
| Lilly USA, LLC | 2 | $25 |
| Gilead | 2 | $24 |
| EMD Serono, Inc. | 2 | $24 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Genmab U.S., Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $15 |
| AVEO Pharmaceuticals, Inc. | 1 | $15 |
| TG Therapeutics, Inc. | 1 | $13 |
| Dendreon Pharmaceuticals LLC | 1 | $12 |
| Taiho Oncology, Inc. | 1 | $12 |
| Astellas Pharma US Inc | 1 | $12 |
| Agios Pharmaceuticals, Inc. | 1 | $12 |
| Bayer | 1 | $12 |
| Pfizer | 1 | $11 |
| Clovis Oncology, Inc. | 1 | $10 |
| Heron Therapeutics, Inc. | 1 | $9 |
How this compares
$1,806 in reported general payments places this provider in the 45th percentile of 75 hematology & oncology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 13 | $212,182 |
| Anastrozole | 43 | $501 |
| Letrozole | 20 | $280 |
| Hydroxyurea | 19 | $218 |
| Dexamethasone | 25 | $168 |
| Ondansetron Hcl | 16 | $133 |
| Prednisone | 19 | $76 |
| Potassium Chloride | 12 | $26 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Sioux City
- Donald WenderSioux City$1.3M
- Nibash BudhathokiSioux City$5K
- Chandana JavvajiSioux City$1K
- Umang SwamiIowa City$9.7M
- Mohammed MilhemIowa City$6.4M
- Umar FarooqIowa City$4.4M
- Varun MongaIowa City$3.6M
- Douglas LauxIowa City$3.3M
- Christopher StrouseIowa City$2.3M
- Mark KarwalIowa City$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.